Study S003303

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Repeated Subcutaneous Doses of SAR425899 in Healthy Male Subjects and Overweight to Obese Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT02411825
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 76
Start: 2015-03
Primary completion: 2016-01
Lead sponsor: Sanofi
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:SAR425899; DRUG:placebo; DRUG:metformin
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2014-004216-10; OTHER:U1111-1163-1209; NIH:2014

Registered primary outcomes

Number of adverse events [28 to 35 days]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0029871	Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes. Visentin R, Diabetes, obesity & metabolism	2020	Randomized trial	PMID 31808298 DOI	cites ClinicalTrials.gov:NCT02411825; registry reference DERIVED:31808298
R0025321	A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. Tillner J, Diabetes, obesity & metabolism	2019	Randomized trial	PMID 30091218 DOI	cites ClinicalTrials.gov:NCT02411825; registry reference DERIVED:30091218
R0048008	Effects of the Novel Dual GLP-1R/GCGR Agonist SAR425899 on Postprandial Glucose Metabolism in Overweight/Obese Subjects with Type 2 Diabetes Britta Goebel, Diabetes	2018	Randomized trial	DOI	cites ClinicalTrials.gov:NCT02411825